ABSTRACT Obstructive sleep apnoea is a risk factor for pulmonary embolism. Elevated D-dimer levels and other biomarkers are associated with recurrent pulmonary embolism.
Introduction
There is increasing evidence from cross-sectional and longitudinal studies that obstructive sleep apnoea (OSA) is a risk factor for pulmonary embolism (PE) independent of potential confounders [1] [2] [3] [4] [5] .
The annual incidence of PE is one to two cases per 1000 person-years, and it is strongly age dependent. PE and OSA share risk factors (advanced age, physical inactivity and obesity) [6, 7] , its association represent a major public health burden, given its high prevalence and increased mortality rates [7, 8] , which is likely to rise as the population ages and obesity rates increase in developing and emerging countries. Patients with a first episode of PE have a cumulative recurrence rate circa to 25% at 5 years [9] . Recurrent PE is associated with mortality rates of 4-9%, and it is also a risk factor for chronic pulmonary hypertension. Anticoagulants are highly effective in decreasing the PE recurrence rate; however, it increases the risk of bleeding complications and, therefore, the optimal length of anticoagulation following PE remains unclear.
D-dimer is a fibrin degradation product that is used to evaluate patients with suspected PE. It has also reported a higher risk of PE recurrence in patients with unprovoked PE who had a high post-anticoagulation D-dimer (>500 ng·mL −1 ) than in patients with normal D-dimer levels [10] . A landmark randomised clinical trial found that patients with an abnormal D-dimer test who restarted anticoagulation had a significantly lower combined incidence of recurrent venous thromboembolism and bleeding than those who did not resume the treatment [11] . Thus, D-dimer has been proposed as a tool in guiding the length of therapy for PE.
The prognostic role of other biomarkers of haemostasis/fibrinolysis is less known. Elevated levels of prothrombin fragment 1+2 (F1+2) and soluble P-selectin (sP-selectin) have been explored as a risk factor for first and recurrent thromboembolic events, but studies have reported conflicting results [12] [13] [14] [15] .
Based on the aforementioned features and considering that OSA leads to a hypercoagulable state, we hypothesised that those patients discontinuing anticoagulation after a PE with OSA could have a greater risk of embolic recurrence, evidenced by the presence of a high level of D-dimer, than non-apnoeic subjects. The main objective of the present study was to compare the frequency of elevated plasma levels (>500 ng·mL ) of D-dimer after oral anticoagulation withdrawal for a first PE episode in patients with and without OSA, including two control groups without PE, one with OSA and one with no sleep-breathing problems.
Methods

Subjects, design and ethics
We performed a prospective matched case-control study (University Hospital Son Espases, Palma de Mallorca and University Hospital La Paz, Madrid, Spain). Eligible cases were all patients with a previous (6-12 months) PE episode diagnosed by computed tomography (CT) pulmonary angiography that had completed at least 3 months with a vitamin K antagonist. They were included if they stopped anticoagulation for at least 1 month. Patients were excluded if they were unwilling or unable to participate in the study, estimated survival <12 months, and/or severe daytime hypoxaemia (arterial oxygen tension <60 mmHg).
Controls were population-based volunteers. They were enrolled from the population area of the Primary Care Centres. They were never previously evaluated with a sleep study. We randomly selected a subject without previous diagnosis or clinical suspicion of thromboembolic disease, with similar in sex, age (±2 years), weight (±2 Kg) and height (±5 cm) with regard to the two preceding PE patients included in the study and who had no exclusion criteria e.g. a very serious illness (terminal or serious physical/mental disability) that might prevent monitoring and participation in the study, inability to sign the informed consent and/or treatment with vitamin K antagonists, and those with communication or comprehension difficulties.
The study was approved by the Institutional Ethics Committee at the hospital and all subjects (cases and controls) gave their written informed consent.
Measurements
A validated portable recording sleep monitoring system (Stardust II; Respironics, Inc., Murrysville, PA, USA) was used to perform a sleep study in all patients and control subjects. Every patient or control was classified as having OSA when the obstructive component was dominant and apnoea-hypopnoea index (AHI) was ⩾5·h −1 (see online supplementary material).
In all subjects anthropometric, clinical and sleep data were collected. We recorded, for all subjects, all the potential confounders which included: sex, age, body mass index (BMI), neck diameter, physical activity level, classic risk factors for pulmonary embolism ( prolonged immobilisation major surgery, trauma, cancer, major medical diseases, hormone replacement, oral contraceptive therapy and cerebrovascular disease), blood pressure values, and forced expiratory volume in 1 s (FEV1) measured as % predicted. . Plasma levels of soluble P-selectin (sP-selectin), thrombin-antithrombin complex (TAT), plasminogen activator inhibitor 1 (PAI-1), and F1+2, were determined by an enzyme-linked immunoassay (MAGPIX Multiplex Immunoassay, Merck Millipore, Dormstadt, Germany) according to manufacturer's instructions with Xponent software 4.1. Commercial kit R&D Systems Quantikine (Minneapolis, MN, USA) was used to measure sP-selectin (Human soluble P-Selectin/CD62P Immunoassay) and PAI-1 (Human Serpin E1/PAI1) and for the quantitative determination of human prothrombin fragment F1+2 and TAT the commercial kit Enzygnost (SIEMENS Healthcare Diagnostics, Marburg, MN, Germany) was used. Measurements were always done in duplicate and the measured values were used for analysis. Intra-assay/inter-assay coefficient variation (CV) for the techniques used were: sP-selectin (5.2-8.8% CV); TAT (5-7.5% CV); PAI-1 (6.7-7.3% CV); F1+2 (4.5-7.8% CV); D-dimer (4.2-5% CV).
Statistical analysis
The normality of the distribution of variables was tested using the Kolmogorov-Smirnov test. Continuous variables were expressed as mean±SD or median (interquartile range), depending on their distribution. Categorical variables were reported as absolute numbers and percentages. Differences between study groups for qualitative and quantitative variables were analysed by the Chi-squared test and analysis of variance with Bonferroni post hoc test, respectively. The relationship between plasma levels of biomarkers and sleep parameters was determined using multiple linear regression analysis after normalisation of all variables by log transformation and adjustment for classic risk factors for PE. To examine associations between study groups and the study variables, odds ratios (OR) and 95% confidence intervals (CI) in univariate and multivariate analyses were calculated by logistic regression. Statistical significance was assumed for p<0.05. All analyses were performed using the Statistical Package for the Social Sciences, version 13.0 software (SPSS Inc., Chicago, IL, USA).
Pulmonary embolism patients evaluated n=130
Pulmonary embolism patients included n=86
Non-OSA n=22
OSA n=64
No response n=1
Home oxygen therapy n=1
Terminal neoplasm n=4
Technical sleep study crop-out n=4
Vitamin K antagonists n=21
Patient refusals n=11
Control subjects evaluated n=127
Control subjects included n=89
Non-OSA n=48 
Results
From the 107 patients with PE and the 102 control subjects [1] we excluded 21 PE patients, who were on vitamin K antagonist, and 13 control subjects, who were without blood samples. All patients were under oral anticoagulation with acenocoumarol. Therefore, 86 patients with PE and 89 control subjects were finally included in the study ( figure 1 ). There were no significant differences between patients with PE and control subjects in the anthropometric characteristics (age, sex, BMI, smoking, and alcohol intake).
General characteristics
Overall, 64 (74.4%) PE patients and 41 (46.1%) control subjects had OSA (apnoea-hypopnoea index >5·h
) (figure 1). Subjects were classified in four study subgroups: 1) PE-OSA (PE patients with OSA), 2) PE non-OSA (PE patients without OSA), 3) C-OSA (control subjects with OSA) and 4) C non-OSA (control subjects without OSA). The four subgroups were homogenous in sex, BMI and daily physical activity level. OSA patients (PE-OSA and C-OSA) were older than non-OSA subjects (tables 1 and S1).
Sleep study variables
By definition AHI was significantly higher in OSA patients (PE-OSA and C-OSA) compared with non-OSA. In addition, OSA patients (PE-OSA and C-OSA) had worse nocturnal oxygen saturation indices than non-OSA subjects. PE-OSA also had higher desaturation index and lower mean night-time SaO 2 than C-OSA (22.9±17.2 event·h −1 versus 15.7±14.0 event·h
, and 92.6±2.4 versus 94.0±1.9%, respectively; p<0.05) (table  1) . Lastly, no differences were found in daytime somnolence. 
Haematological and biochemical analysis
The number of circulating erythrocytes, leucocytes and platelets were similar between groups. Dyslipidaemia was significantly more frequent in the PE group than in controls, with both higher triglycerides and lower high-density lipoprotein (HDL)-C levels. C-OSA had lower HDL-C values compared with C non-OSA. Furthermore, uric acid levels were also higher in PE-OSA than C non-OSA subjects ( p<0.05) (table 1) .
Procoagulant, platelet activity and fibrinolysis biomarkers
The primary outcome of our study was to compare the percentage of patients with elevated D-dimer between the study groups. The prevalence of elevated levels of D-dimer (>500 ng·mL −1 ) after stopping anticoagulant treatment for PE was higher in patients with OSA than in patients without OSA (35.4% versus 19%, p=0.003). In the same way, C-OSA had a higher percentage of subjects with high D-dimer levels than C non-OSA (figure 2). PE patients with OSA had significantly greater D-dimer plasma concentrations than non-OSA (with or without previous PE, 355 ng·mL −1 (230-615 ng·mL ); p<0.01 and p<0.05, respectively). F1+2 and PAI-1 levels were also higher in patients with PE and OSA compared with those who did not have a PE (with or without OSA) (table 1). Furthermore, TAT was also higher in PE than controls without PE (table 1).
In patients with PE, AHI was related to high D-dimer levels (table 2). This association remained significant after adjusting for sex, age, BMI, neck diameter, physical activity level, classic risk factors for pulmonary embolism, blood pressure values and FEV1 % pred, adjusted OR 1.114 (95% CI 1019-1218, p=0.018).
The relationships between plasma levels of haemostasis/fibrinolysis biomarkers and sleep parameters, adjusted for the classic risk factors for PE, are shown in table 3. In all study subjects, D-dimer levels were directly related to AHI (r=0.279, p=0.007), percentage of total time study spent with SaO 2 <90% and desaturation index and inversely related to the mean and minimum night-time SaO 2 (figure 3). A significant relationship was also found between AHI and the sP-selectin level. In addition, other significant relationships were found between some indices of nocturnal oxygen saturation and PAI-1 and F1+2 levels (table 3) . In a multiple linear regression analysis, adjusted for sex, age, BMI and classic risk factors for pulmonary embolism, we found that D-dimer levels were mainly determined by AHI (β=0.22, p=0.02, ΔR 2 =0.12) and minimum night-time SaO 2 (β=−0.25, p=0.011, and ΔR 2 =0.04), whereas the mean sleep SaO 2 , Epworth Sleepiness Scale and the percentage of total study time spent with SaO 2 <90% were the main determinants of F1+2 levels (table 4) .
Finally, we evaluated the relationship between procoagulant, platelet activity and fibrinolysis biomarkers and sleep characteristics in the subgroup of subjects with OSA and excessive sleepiness (AHI >5 h −1 and ESS >11). After adjusting for classic risk factors for PE, D-dimer remained significantly related with AHI (r=0.631, p=0.037) (figure S1), desaturation index (r=0.631, p=0.021) and mean and minimum night-time SaO 2 (r=−0.515, p=0.049; r=−0.534, p=0.049, respectively). In these patients, AHI was also related to sP-selectin levels (r=0.658, p=0.020) (figure S1), whereas ESS was significantly correlated with PAI-1 (r=0.651, p=0.041), F1+2 (r=0.746, p=0.008) and TAT (r=0.617, p=0.033).
Discussion
In this study, we have shown that PE patients with OSA had higher rates of elevated D-dimer levels (>500 ng·mL −1 ) after anticoagulation discontinuation for PE than in patients without OSA. Furthermore, ) in patients with pulmonary embolism after anticoagulation discontinuation and in control subjects. D-dimer levels were higher in OSA patients than in patients without OSA. D-dimer concentrations were directly related to the severity of OSA, and inversely correlated with nocturnal hypoxia.
There is increasing evidence from cross-sectional and longitudinal studies, that OSA is an independent risk factor for PE [1] [2] [3] [4] [5] . We have recently shown in a group of 107 PE patients significantly higher prevalence in all OSA severity groups when compared with controls.
We found significant association between AHI and PE after adjustment for the main confounding factors. The adjusted OR using AHI as a continuous variable was 1.038, which indicated that for every 10-unit rise in AHI, PE risk increased by 45% [1] .
The mechanisms explaining this novel association between PE and OSA are unclear. PE is the result of Virchow's classic risk triad, namely vascular endothelial impairment, stasis of blood flow, and/or increased coagulability [16] . OSA could potentially play a role in all these three mechanistic pathways. Apnoea increase oxidative stress [17] , and activate inflammatory cascade that impairs endothelial function [18] . OSA-related haemodynamic alterations may slow intravenous flow [19] , and lastly, cross-sectional studies support increased coagulability, platelet activity and aggregability [20, 21] and decreased fibrinolytic capacity in OSA. It has also been shown that that coagulant activity, platelet function and fibrinolytic system are improved after continuous positive airway pressure (CPAP) [20] [21] [22] [23] [24] [25] . However, the associations with OSA and changes with CPAP have not been uniformly established for all biomarkers [24] [25] [26] .
D-dimer is a major plasmin-derived degradation product of cross-linked fibrin. Its generation depends on the presence of fibrin and plasmin. The level of D-dimer is considered to reflect the global activity of clot formation and lysis [10] .
SHITRIT et al. [27] selected 103 OSA patients and found high D-dimer levels in 14. The subgroup with high D-dimer levels had lower minimal oxygen saturation and a longer mean period with SaO 2 <90% in the sleep study compared with normal D-dimer OSA group [27] . In keeping with these results, it has been shown that D-dimer increased significantly when patients were exposed to hypoxic conditions [28] . Other investigators have found augmented fibrinogen levels in both adults and children with OSA [29] [30] [31] , which decreased after CPAP treatment [22] . However, these findings are not uniform with several studies showing no, or even inverse, associations between OSA and D-dimer [30, 32, 33] , while a number of reports did not find changes after CPAP [24, [32] [33] [34] . We also found significantly higher D-dimer plasma [35, 36] . OSA is associated to sedentary lifestyle and obesity that may induce a procoagulant state and venous stasis, which have been associated with an increased risk of PE [7] . Moreover, it is tempting to speculate that nocturnal hypoxaemia in OSA patients may lead to up-regulation of procoagulant activity in valvular sinus in deep veins.
The conflicting results in D-dimer in OSA may be explained by differences in populations and sampling (concomitant comorbidities, sex distribution, age, BMI and varying degrees of sleep apnoea severity). Besides, non-dipping blood pressure profile at night and emotional and mood factors are associated with elevated D-dimer [37, 38] , and the impact of these aspects has not been systematically evaluated in the majority of the studies.
The main finding of our study (higher proportion of subjects with elevated post-anticoagulation D-dimer in PE-OSA compared with PE non-OSA) may have important clinical implications. In patients with a first PE event, an elevated D-dimer level after anticoagulation is stopped is a risk factor for recurrent PE [10] . A randomised clinical trial has shown that patients with an abnormal D-dimer test and who restarted anticoagulation had a significantly lower combined incidence of recurrent venous thromboembolism and bleeding, than those who did not resume the treatment [11] . Therefore, it has been suggested to use this biomarker as a tool to choose the extent of anticoagulation. We hypothesise that those patients with PE and concomitant OSA have an increased risk of future PE episodes, and it could be used to identify patients with a high risk of recurrence and who might require longer anticoagulant treatment.
Other global coagulation markers activation and fibrinolysis, such as TAT, sP-selectin, PAI-1 and F1+2, have been explored as predictors of recurrent venous thromboembolism, but are not yet ready for clinical use [12] [13] [14] [15] .
Several studies have shown increased sP-selectin, PAI-1 and TAT levels in OSA [23, 25, 26, 28, 30, 32] . However, there are conflicting results [24, 26] . But, overall, most studies have confirmed that OSA is associated with a procoagulant state.
We could not demonstrate any difference in sP-selectin, F1+2, PAI-1, and TAT between OSA and non-OSA subjects. Consequently, we found no imbalance in platelet activation, fibrinolysis system and thrombin generation. However, there were significant correlations between sP-selectin, PAI-1, F1+2 and TAT and some indices of nocturnal hypoxaemia. These could be explained because they are really unrelated, or because the present study might have had limited power to detect differences. The precise processes that initiate venous thrombosis remain uncertain. Several studies have shown increased markers of coagulation activation and platelet activity such as D-dimer, TAT and F1+2, and sP-selectin in conditions with enhanced thrombin formation [39] . A single abnormality factor is seldom enough to cause venous thrombosis, as it may require a synergy of several factors. TOUKH et al. [40] used thromboelastography to assess coagulability, which provides information about the full spectrum of the haemostatic process, (from the initial formation of fibrin until lysis of the clot) and found that OSA patients had a procoagulant state that was reduced after 2 weeks of CPAP. As a result, there may be a thrombosis threshold where the trend to cause thrombin is not effectively regulated by antithrombotic mechanisms.
There are a number of limitations that should be considered in relation to our study, beyond sample size, which limits some ancillary subanalyses. First, there is a marked diurnal variability in procoagulant factors in OSA [32, 33, 41] . We did single time-point assessments, but whole samples in all subjects were collected after fasting overnight between 08:00 and 10:00 h, and single sample assessments of elevated D-dimer have been prospectively related with an increased risk of recurrent PE in several studies [10] . Second, although we designed our study to evaluate coagulation markers in addition to our primary outcome of association between OSA and PE, the selection of these biomarkers was determined post hoc, thus the study may have been underpowered to find out changes in some hypercoagulable state mediators. Third, although cross-sectionally high D-dimer concentration in OSA patients compared with non-OSA subjects is consistent with a procoagulant state, any cause-effect relationship would require confirmation in prospective longitudinal cohort studies. Fourth, although OSA diagnosis was based on type 3 portable sleep monitoring system without electroencephalographic signals, it has been previously validated. Both patients and controls were studied with the same device and protocol, which could underestimate the severity of OSA and the relationships that we have found between D-dimer level and OSA severity. Finally, we acknowledge our patients have comorbidities that could affect the values of some of the biomarkers tested. However, the groups were quite similar and we selected consecutive PE patients that correspond to the real-life entire clinical disease spectrum of PE.
To conclude, we have found that PE patients with associated OSA had a higher proportion of subjects with high post-anticoagulation D-dimer, than in those without OSA. Moreover, D-dimer levels were higher in PE patients with associated OSA than without, indicating that there is a persistent hypercoagulable state in OSA. Data from new studies are needed to definitively clarify if OSA is a risk factor for PE recurrence, particularly in those ones with high D-dimer values. Given the high prevalence of OSA in PE patients [1] [2] [3] [4] [5] , the increased blood coagulability induced by OSA, and the raised percentage of patients with elevated D-dimer levels after the completion of anticoagulation, the potential of CPAP and/or resumption anticoagulant drugs to reduce incidence and mortality in patients with OSA clearly warrants further study, in particular for patients with previous PE.
